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High-Dose Vitamin C Promotes Regression of Multiple 
Pulmonary Metastases Originating from  
Hepatocellular Carcinoma
Min-Seok Seo1,2, Ja-Kyung Kim3, and Jae-Yong Shim1
Departments of 1Family Medicine and 3Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul; 
2Yonsei University Graduate School of Medicine, Seoul, Korea.
We report a case of regression of multiple pulmonary metastases, which originated from hepatocellular carcinoma after treat-
ment with intravenous administration of high-dose vitamin C. A 74-year-old woman presented to the clinic for her cancer-related 
symptoms such as general weakness and anorexia. After undergoing initial transarterial chemoembolization (TACE), local recur-
rence with multiple pulmonary metastases was found. She refused further conventional therapy, including sorafenib tosylate 
(Nexavar). She did receive high doses of vitamin C (70 g), which were administered into a peripheral vein twice a week for 10 
months, and multiple pulmonary metastases were observed to have completely regressed. She then underwent subsequent 
TACE, resulting in remission of her primary hepatocellular carcinoma.
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INTRODUCTION
Ascorbate (vitamin C) is a fundamental vitamin for human life 
as an important antioxidant by blocking damage from free radi-
cals,1 and acts as a cofactor for hydroxyl enzymes in collagen 
synthesis which has been thought to prevent tumor spread-
ing.2,3 On the other hand, high-dose vitamin C can act as a pro-
oxidant, conferring selective toxic effects on cancer cells.4 Also, 
it may exert anti-inflammatory activity resulting in suppression 
of tumor proliferation, angiogenesis, and metastasis.5 High-
dose vitamin C supplementation has been widely used as com-
plementary and alternative medicine, particularly in cancer 
patients.6 Although there is a paucity of clinical research data to 
confirm the effects of vitamin C on cancer, some interesting 
case reports have suggested the clinical prospect of high-dose 
vitamin C therapy.7,8 One of these is similar to our report, except 
it involved multiple pulmonary metastases originating from re-
nal cell cancer.8 Here, we report a case of regression of multiple 
pulmonary metastases originating from hepatocellular carci-
noma after high-dose vitamin C therapy.
CASE REPORT
A 74-year-old woman was found to have a 2.2-cm liver mass 
with multiple satellite nodules (T2N0M0) on abdominal-pelvic 
CT (APCT) in January 2011 (Fig. 1A). Protein induced by vita-
min K absence or antagonist-II (PIVKA II) was within normal 
range, 28 mAU/mL, but alpha fetoprotein (AFP), 4040.05 ng/
mL, was high, and anti-hepatitis C virus was positive. The pa-
tient initially received transarterial chemoembolization (TACE) 
in February 2011, but locally recurrent hepatocellular carcino-
ma with multiple pulmonary and mediastinal lymph node me-
tastases were found on positron emission tomography-com-
puted tomography (PET-CT) scan in July 2011 (Fig. 2A and B) 
and APCT in September 2011 (Fig. 1B). She refused further 
treatment, including sorafenib tosylate (Nexavar, Bayer Health-
Care AG, Leverkusen, Germany), and then visited our clinic 
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with anorexia and general weakness in September 2011 re-
questing high-dose vitamin C to manage her symptoms. Twen-
ty grams of vitamin C in 250 mL normal saline was initially ad-
ministered via an ante-cubital vein twice a week in September 
2011 after urine analysis and renal function were confirmed to 
be within normal range. To neutralize acidic pH (3.5–5.0) of vi-
tamin C, it was mixed with NaHCO3, resulting in pH 6.2 (UniC®, 
500 mg/mL from Unimed Pharmaceuticals, Seoul, Korea). In 
addition, normal saline was changed to distilled water as vita-
min C dose increased to avoid too much intake of volume and 
sodium and too high concentration. Furthermore, magnesium 
sulfate 1 g was blended in the fluid to prevent vascular irrita-
tion.9 Notably, she did not have glucose-6-phosphate dehydro-
genase deficiency. Prior to April 2012, no significant progres-
sion or regression of her multiple pulmonary metastases was 
found on serial chest X-ray, although she reported improved 
general wellbeing. In July 2012, multiple pulmonary nodules 
were found to have completely regressed on chest X-ray (Fig. 
2C), which was confirmed on PET-CT scan in September 2012 
(Fig. 2D). However, a 5.5-cm hepatic mass still remained on ab-
domen ultrasound and PET-CT scan (Fig. 1C). Considering her 
good performance status, we recommended repeated TACE, 
but she declined. Therefore, high-dose vitamin C administra-
tion was continued for more than a year. In July 2013, she finally 
decided to undergo TACE in addition to the high-dose vitamin 
C treatment. Subsequently, three rounds of TACE were per-
formed. After the fourth round of TACE, the hepatic mass was 
found to have entirely regressed (Fig. 1D), and both PIVKA II 
and AFP levels had returned to normal range. The serial chang-
es in AFP and PIVKA II levels are shown in Table 1. The patient 
denied any use of other anti-cancer medications or alternative 
therapies except pain medication for her intermittent abdomi-
nal pain. She was quite tolerant of high-dose vitamin C during 
the entire treatment period, but thirst was an occasional com-
plaint, which was easily remedied by water intake. 
DISCUSSION
In the 1970s, Cameron and Pauling reported that high-dose 
vitamin C had therapeutic effects in cancer.10 Early clinical 
studies showed that high-dose vitamin C administration con-
ferred survival benefit compared to control groups.11,12 How-
ever, a subsequent clinical study at Mayo Clinic failed to show 
significant differences in survival between an oral vitamin C 
administration group and the control group.13 In addition to 
Fig. 1. Serial abdominal CT scan. (A) A 2.2-cm mass is shown in S7 of the liver (initial diagnosis, Jan-29-2011). (B) Recurrence of the tumor was shown in a 
previous TACE-treated lesion (Sep-05-2011). (C) Recurrent hepatocellular carcinoma remained visible on PET-CT scan after the regression of multiple lung 
metastases with vitamin C administration (Sep-13-2012). (D) Hepatocellular carcinoma regressed completely after the fourth TACE treatment (Jan-28-
2014). TACE, transarterial chemoembolization; PET-CT, positron emission tomography-computed tomography.
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these studies in which oral vitamin C was tested, a recent phar-
macokinetic study suggests that high concentrations of intra-
venous vitamin C are toxic to cancer cells.14 Hoffer, et al.15 re-
ported that when 1.5 g/kg of vitamin C was administered, 
plasma concentrations over 10 mM could be maintained for 
4.5 hours. Some authors suggest that the oral administration of 
vitamin C at the Mayo Clinic could have failed to achieve effec-
tive plasma concentrations, and that effective concentrations 
Table 1. Serial Tumor Markers
Date Event AFP (ng/mL) (1.1–5.0 ng/mL) PIVKA II (mAU/mL) (0–35 mAU/mL)
Jan-25-2011 Diagnosis 4040.05 28
Feb-25-2011 First TACE - -
Jun-09-2011 3164.85 -
Sep-05-2011 Recurrence of primary cancer & multiple lung metastases 25604.73 -
Oct-07-2011 Vitamin C administration (70 g) >54000 -
Jul-25-2012 Regression of multiple lung metastases on chest X-ray - -
Dec-18-2012 >54000 -
Jul-25-2013 Second TACE - -
Oct-01-2013 6439.0 287
Sep-02-2013 Third TACE - -
Sep-23-2013 4594.0 476
Jan-07-2014 Fourth TACE - -
May-30-2014 3.2 28
AFP, alpha fetoprotein; PIVKA II, protein induced by vitamin K absence or antagonist II; TACE, transarterial chemoembolization.
Fig. 2. Multiple well-defined nodules are evident in both lung fields on chest radiography (A) and chest CT scan (B) in September 2011, before the initiation 
of intravenous high-dose vitamin C treatment. Chest radiography in July 2012 (C) and chest CT in February 2013 (D) showing regression of the lesions.
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can only be reached by intravenous administration.16 There-
fore, further clinical studies to evaluate the anti-cancer effects 
of intravenous high-dose vitamin C are warranted.
Potential mechanisms of action of vitamin C on cancer cells 
remains uncertain, but recent experimental data suggest 
some possible mechanisms. First, vitamin C has a pro-oxidant 
effect at higher concentrations. Chen, et al.17 reported that 
high-dose vitamin C generated hydrogen peroxide (H2O2) in 
the extracellular fluid, which then entered into cells. H2O2 is 
able to accelerate the production of additional reactive oxy-
gen species (ROS) such as aldehydes. These ROS are capable 
of several effects, including DNA damage, cell membrane dys-
function, and cellular adenosine triphosphate depletion in 
cancer cells due to reduced levels of antioxidant enzymes such 
as glutathione peroxidase, superoxide dismutase, and catalase. 
These processes are not found in normal cells and may lead to 
death of cancer cells.18,19 Second, vitamin C may modulate in-
flammation resulting in increase of host resistance to cancer. 
Cho, et al.20 demonstrated that highly concentrated vitamin C 
decreased the production of interleukin-18, which is related to 
tumor cell growth, proliferation, and migration. Chen, et al.21 
reported that the expression of hypoxia-inducible factor-1α 
protein, which is associated with tumor growth, is inhibited by 
vitamin C in an animal study. In addition, Mikirova, et al.22 dem-
onstrated that C-reactive protein level which is correlated with 
disease activity was reduced after high-dose vitamin C treat-
ment in cancer patients.
In conclusion, we describe a case of regression of multiple 
pulmonary metastases after treatment with high-dose vitamin 
C, which enabled a subsequent trial of TACE, eventually lead-
ing to complete remission of the primary hepatocellular carci-
noma. Notably, intravenous vitamin C administration has an 
advantage in terms of safety compared to other conventional 
cancer therapies. Our patient did not show any complications 
or serious side effects, except for mild thirst. Although there is 
controversy over the effect of vitamin C on cancer, intrave-
nous administration of high-dose vitamin C could be at-
tempted in patients who refuse conventional therapy. Also, 
we hope to find a common denominator in accumulated case 
reports that might offer clues to which cases vitamin C ad-
ministration could be an effective cancer therapy. 
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